ACXP Insider Trading Activity and SEC Form 4 Filings
ACXP insider trading summary
No open-market insider purchases or sales of Acurx Pharmaceuticals, Inc. (ACXP) have been reported on SEC Form 4 in the past 12 months.
Latest ACXP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 6, 2025 | Robert J Deluccia | Director | Buy | $50K (49,261 @ $1.01) |
| Jan 6, 2025 | Joseph C Scodari | Director | Buy | $25K (24,631 @ $1.01) |
| Jan 6, 2025 | David P Luci | President and CEO | Buy | $50K (49,261 @ $1.01) |
| Jan 6, 2025 | Jack H Dean | Director | Buy | $10K (9,852 @ $1.01) |
| Jan 6, 2025 | Carl Sailer | Director | Buy | $25K (24,631 @ $1.01) |
| Jan 6, 2025 | James J. Donohue | Director | Buy | $10K (9,852 @ $1.01) |
| Jul 27, 2022 | David P Luci | President and CEO | Buy | $75K (19,737 @ $3.80) |
| Jul 27, 2022 | Robert J Deluccia | Director | Buy | $75K (19,737 @ $3.80) |
| Jul 27, 2022 | Carl Sailer | Director | Buy | $75K (19,737 @ $3.80) |
| Nov 23, 2021 | Carl Sailer | Director | Buy | $25K (5,161 @ $4.84) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.